Roche terminates licensing agreement with AC Immune
The Lausanne-based, Nasdaq-listed company said the healthcare giant's decision would not prevent it from pursuing phase 2 development of its immunotherapies, for which it will take over full rights.
Following its $50 million capital increase completed last month, AC Immune believes it is sufficiently funded to continue its activities until 2026.
The partnership with Roche concerned crenezumab, a humanized monoclonal antibody designed to slow the progression of Alzheimer's disease by neutralizing neurotoxic beta-amyloid oligomers.
It also concerned semorinemab, another 'anti-Tau' antibody targeting the N-terminus of the Tau protein, designed to narrow the space between neurons.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction